KYPROLIS®
(carfilzomib) for injection

Kyprolis is a next-generation proteasome inhibitor, approved by the FDA in the following settings:

- In combination with dexamethasone, or with Revlimid® (lenalidomide) + dexamethasone (Rd), for the treatment of patients with relapsed or refractory myeloma who have received one to three prior lines of therapy.
- As a single agent for the treatment of patients with relapsed or refractory myeloma who have received one or more prior lines of therapy.

Dosing regimens and schedules

- **Once-weekly, 20/70 mg/m² by 30-minute infusion:** 20 mg/m² of Kyprolis is given for the first dose (Cycle 1, day 1), then 70mg/m² is given once weekly on days 8 and 15. From Cycle 2 onward, Kyprolis is given at 70 mg/m² on days 1, 8, and 15 of each 28-day cycle. No Kyprolis is given on days 16–28 of any cycle. 40 mg of dexamethasone is given on days 1, 8, 15, and 22 of Cycles 1–9. Thereafter, dexamethasone is given only on days 1, 8, and 15 of each 28-day cycle.
- **Twice-weekly, 20/56 mg/m² by 30-minute infusion** (Kyprolis + dexamethasone, or Kyprolis monotherapy): 20 mg/m² of Kyprolis on days 1 and 2 of Cycle 1, then, if tolerated, the Kyprolis dose is escalated to 56 mg/m² on days 8 and 9, 15 and 16. From Cycle 2–12, Kyprolis is given at 56 mg/m² on days 1 and 2, 8 and 9, and 15 and 16 of each 28-day cycle. From Cycle 13 onward, Kyprolis is given at 56 mg/m² on days 1 and 2, 15 and 16 of each 28-day cycle. No Kyprolis is given on days 17–28 of any cycle. If you are also taking dexamethasone, it is given at 20 mg per day on days 1 and 2, 8 and 9, 15 and 16, and 22 and 23 of each 28-day cycle.
- **Twice-weekly, 20/27 mg/m² by 10-minute infusion** (Kyprolis monotherapy): Kyprolis is given at a dose of 20 mg/m² on Cycle 1, days 1 and 2. If tolerated, the dose is escalated to 27 mg/m² on days 8 and 9, 15 and 16 of the first cycle. In Cycles 2–12, Kyprolis is given at 27 mg/m² on days 1 and 2, 8 and 9, 15 and 16 of each 28-day cycle. From Cycle 13 onward, Kyprolis is given at 27 mg/m² on days 1 and 2, 15 and 16 of each 28-day cycle. No Kyprolis is given on days 17–28 of any cycle.

(continues on reverse side)

- **Twice-weekly in combination with Rd by 10-minute infusion**: During Cycle 1, Kyprolis is given at 20 mg/m^2 on days 1 and 2, and if tolerated, at 27 mg/m^2 on days 8 and 9, 15 and 16. In Cycles 2–12, Kyprolis is given at 27 mg/m^2 on days 1 and 2, 8 and 9, 15 and 16 of each 28-day cycle. From Cycle 13 onward, Kyprolis is given at 27 mg/m^2 on days 1 and 2, 15 and 16 of each 28-day cycle. No Kyprolis is given on days 17–28 of any cycle. Dexamethasone is given at 40 mg on days 1, 8, 15, and 22 of each 28-day cycle. Revlimid is given at 25 mg on days 1–21 of each 28-day cycle.

Precautions

- You will be pretreated with dexamethasone prior to all cycle 1 doses and if infusion reaction symptoms appear.
- You should drink water at a rate of 30 milliliters (1 ounce) for every kilogram (2.2 pounds) of your body weight at least 48 hours before your first infusion.
- You will receive medication to prevent blood clots if you are taking Kyprolis in combination with dexamethasone or with Rd.
- You should receive antiviral therapy to decrease the risk of shingles.
- If you are receiving hemodialysis for kidney failure, you should receive Kyprolis after the hemodialysis procedure.

The most common side effects

- Fatigue, anemia, nausea, thrombocytopenia, shortness of breath, diarrhea, and fever.
- Dizziness, fainting, or a drop in blood pressure. If you experience any of these symptoms, do not drive or operate machinery.

Other serious side effects

Renal (kidney) insufficiency and cardiac issues, including heart failure, have been reported in clinical trial patients. Any concerns about side effects should be discussed with your doctor immediately.

Support

Call Amgen Assist 360™ at 1-888-4ASSIST.

As always, the IMF urges you to discuss all medical issues with your doctor, and to contact the IMF with your myeloma questions and concerns.

International Myeloma Foundation
12650 Riverside Drive, Suite 206, North Hollywood, CA 91607 USA
818.487.7455 800.452.CURE myeloma.org

Improving Lives **Finding the Cure**®

tc-kypro_EN_2019_f2